|
1
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gladson CL, Prayson RA and Liu WM: The
pathobiology of glioma tumors. Annu Rev Pathol. 5:33–50.
2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tanase C, Albulescu R, Codrici E, Popescu
ID, Mihai S, Enciu AM, Cruceru ML, Popa AC, Neagu AI, Necula LG, et
al: Circulating biomarker panels for targeted therapy in brain
tumors. Future Oncol. 11:511–524. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Minniti G, De Sanctis V, Muni R, Filippone
F, Bozzao A, Valeriani M, Osti MF, De Paula U, Lanzetta G,
Tombolini V and Maurizi Enrici R: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma in elderly patients. J
Neurooncol. 88:97–103. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chamberlain MC: Temozolomide: Therapeutic
limitations in the treatment of adult high-grade gliomas. Expert
Rev Neurother. 10:1537–1544. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Prasad G, Sottero T, Yang X, Mueller S,
James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, et al:
Inhibition of PI3K/mTOR pathways in glioblastoma and implications
for combination therapy with temozolomide. Neuro Oncol. 13:384–392.
2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sardiello M, Cairo S, Fontanella B,
Ballabio A and Meroni G: Genomic analysis of the TRIM family
reveals two groups of genes with distinct evolutionary properties.
BMC Evol Biol. 8(225)2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kimsa MW, Strzalka-Mrozik B, Kimsa MC,
Mazurek U, Kruszniewska-Rajs C, Gola J, Adamska J and Twardoch M:
Differential expression of tripartite motif-containing family in
normal human dermal fibroblasts in response to porcine endogenous
retrovirus infection. Folia Biol (Praha). 60:144–151.
2014.PubMed/NCBI
|
|
12
|
Hatakeyama S: TRIM family proteins: Roles
in autophagy, immunity, and carcinogenesis. Trends Biochem Sci.
42:297–311. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu B, Zhang M, Chu H, Zhang H, Wu H, Song
G, Wang P, Zhao K, Hou J, Wang X, et al: The ubiquitin E3 ligase
TRIM31 promotes aggregation and activation of the signaling adaptor
MAVS through Lys63-linked polyubiquitination. Nat Immunol.
18:214–224. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Song H, Liu B, Huai W, Yu Z, Wang W, Zhao
J, Han L, Jiang G, Zhang L, Gao C and Zhao W: The E3 ubiquitin
ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting
proteasomal degradation of NLRP3. Nat Commun.
7(13727)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sugiura T and Miyamoto K: Characterization
of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC
protein. J Cell Biochem. 105:1081–1091. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li H, Zhang Y, Zhang Y, Bai X, Peng Y and
He P: TRIM31 is downregulated in non-small cell lung cancer and
serves as a potential tumor suppressor. Tumour Biol. 35:5747–5752.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang H, Yao L, Gong Y and Zhang B: TRIM31
regulates chronic inflammation via NF-κB signal pathway to promote
invasion and metastasis in colorectal cancer. Am J Transl Res.
10:1247–1259. 2018.PubMed/NCBI
|
|
18
|
Li H, Zhang Y, Hai J, Wang J, Zhao B, Du L
and Geng X: Knockdown of TRIM31 suppresses proliferation and
invasion of gallbladder cancer cells by down-regulating MMP2/9
through the PI3K/Akt signaling pathway. Biomed Pharmacother.
103:1272–1278. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y,
Zhang Y and Han L: TRIM31 is upregulated in hepatocellular
carcinoma and promotes disease progression by inducing
ubiquitination of TSC1-TSC2 complex. Oncogene. 37:478–488.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yu C, Chen S, Guo Y and Sun C: Oncogenic
TRIM31 confers gemcitabine resistance in pancreatic cancer via
activating the NF-κB signaling pathway. Theranostics. 8:3224–3236.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang B, Liu Y, Li Y, Zhe X, Zhang S and
Zhang L: Neuroglobin promotes the proliferation and suppresses the
apoptosis of glioma cells by activating the PI3K/AKT pathway. Mol
Med Rep. 17:2757–2763. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ping YF, Yao XH, Jiang JY, Zhao LT, Yu SC,
Jiang T, Lin MC, Chen JH, Wang B, Zhang R, et al: The chemokine
CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated
VEGF production and tumour angiogenesis via PI3K/AKT signalling. J
Pathol. 224:344–354. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu
N, Xu W, Cui C, Xing Y, Liu Y, et al: Activation of PI3K/Akt
pathway by CD133-p85 interaction promotes tumorigenic capacity of
glioma stem cells. Proc Natl Acad Sci USA. 110:6829–6834.
2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhang P, Chen XB, Ding BQ, Liu HL and He
T: Down-regulation of ABCE1 inhibits temozolomide resistance in
glioma through the PI3K/Akt/NF-κB signaling pathway. Biosci Rep.
38:2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li X, Wu C, Chen N, Gu H, Yen A, Cao L,
Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted
therapy for glioblastoma. Oncotarget. 7:33440–33450.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Dimitrova V and Arcaro A: Targeting the
PI3K/AKT/mTOR signaling pathway in medulloblastoma. Curr Mol Med.
15:82–93. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Cruceru ML, Enciu AM, Popa AC, Albulescu
R, Neagu M, Tanase CP and Constantinescu SN: Signal transduction
molecule patterns indicating potential glioblastoma therapy
approaches. Onco Targets Ther. 6:1737–1749. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, Man
X, Wei F and Yu X: Downregulation of Foxo3 and TRIM31 by miR-551b
in side population promotes cell proliferation, invasion, and drug
resistance of ovarian cancer. Med Oncol. 33(126)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Freed-Pastor WA and Prives C: Mutant p53:
One name, many proteins. Genes Dev. 26:1268–1286. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bieging KT, Mello SS and Attardi LD:
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev
Cancer. 14:359–370. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Chen SR, Cai WP, Dai XJ, Guo AS, Chen HP,
Lin GS and Lin RS: Research on miR-126 in glioma targeted
regulation of PTEN/PI3K/Akt and MDM2-p53 pathways. Eur Rev Med
Pharmacol Sci. 23:3461–3470. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Toledo F and Wahl GM: Regulating the p53
pathway: In vitro hypotheses, in vivo veritas. Nat Rev Cancer.
6:909–923. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Zhang Z, Li M, Wang H, Agrawal S and Zhang
R: Antisense therapy targeting MDM2 oncogene in prostate cancer:
Effects on proliferation, apoptosis, multiple gene expression, and
chemotherapy. Proc Natl Acad Sci USA. 100:11636–11641.
2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hermisson M, Klumpp A, Wick W, Wischhusen
J, Nagel G, Roos W, Kaina B and Weller M: O6-methylguanine DNA
methyltransferase and p53 status predict temozolomide sensitivity
in human malignant glioma cells. J Neurochem. 96:766–776.
2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bleau AM, Hambardzumyan D, Ozawa T,
Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt
pathway regulates the side population phenotype and ABCG2 activity
in glioma tumor stem-like cells. Cell Stem Cell. 4:226–235.
2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li M, Liang RF, Wang X, Mao Q and Liu YH:
BKM120 sensitizes C6 glioma cells to temozolomide via suppression
of the PI3K/Akt/NF-κB/MGMT signaling pathway. Oncol Lett.
14:6597–6603. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Mueller S, Phillips J, Onar-Thomas A,
Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD,
Weiss WA, et al: PTEN promoter methylation and activation of the
PI3K/Akt/mTOR pathway in pediatric gliomas and influence on
clinical outcome. Neuro Oncol. 14:1146–1152. 2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Huang BS, Luo QZ, Han Y, Huang D, Tang QP
and Wu LX: MiR-223/PAX6 axis regulates glioblastoma stem cell
proliferation and the chemo resistance to TMZ via regulating
PI3K/Akt pathway. J Cell Biochem. 118:3452–3461. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wu Y, Dong L, Bao S, Wang M, Yun Y and Zhu
R: FK228 augmented temozolomide sensitivity in human glioma cells
by blocking PI3K/AKT/mTOR signal pathways. Biomed Pharmacother.
84:462–469. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Cioce M, Canino C, Goparaju C, Yang H,
Carbone M and Pass HI: Autocrine CSF-1R signaling drives
mesothelioma chemoresistance via AKT activation. Cell Death Dis.
5(e1167)2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yang H, He L, Kruk P, Nicosia SV and Cheng
JQ: Aurora-A induces cell survival and chemoresistance by
activation of Akt through a p53-dependent manner in ovarian cancer
cells. Int J Cancer. 119:2304–2312. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Guo P, Qiu Y, Ma X, Li T, Ma X, Zhu L, Lin
Y and Han L: Tripartite motif 31 promotes resistance to anoikis of
hepatocarcinoma cells through regulation of p53-AMPK axis. Exp Cell
Res. 368:59–66. 2018.PubMed/NCBI View Article : Google Scholar
|
